A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting now Phase 1 NCT06121843
Run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · for 18 and older · All sexes
What this study is about
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Who can join (things the study team will check)
✅ You may be able to join if…
- History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
- Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
- Eastern Cooperative Oncology Group performance status of 0-1.
🚫 You may not be able to join if…
- Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
- Prior treatment with GPRC5D-targeting therapies.
- Other protocol-defined inclusion/exclusion criteria apply.
Where this trial is running
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Northside Hospital, Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
- University Of Nebraska Medical Center, Omaha, Nebraska, United States
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
+ 7 more sites.
Who to contact
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06121843.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.